MENU
+Compare
IMVT
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$23.86
Change
+$0.06 (+0.25%)
Capitalization
4.04B

IMVT Immunovant Forecast, Technical & Fundamental Analysis

a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.

Industry Biotechnology
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IMVT with price predictions
Jan 08, 2025

IMVT's Indicator enters downward trend

The Aroon Indicator for IMVT entered a downward trend on January 08, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 219 similar instances where the Aroon Indicator formed such a pattern. In of the 219 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMVT's RSI Indicator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.993) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). IMVT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (264.084).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IMVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IMVT is expected to report earnings to rise 1.46% to -75 cents per share on February 12

Immunovant IMVT Stock Earnings Reports
Q4'24
Est.
$-0.75
Q3'24
Missed
by $0.15
Q2'24
Est.
$-0.52
Q1'24
Missed
by $0.09
Q4'23
Beat
by $0.07
The last earnings report on November 07 showed earnings per share of -74 cents, missing the estimate of -58 cents. With 1.03M shares outstanding, the current market capitalization sits at 4.04B.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
320 West 37th Street
Phone
+1 917 580-3099
Employees
164
Web
https://www.immunovant.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MOSLX8.40N/A
N/A
MassMutual Overseas Adm
GGCAX112.30N/A
N/A
Gabelli Growth A
CAMUX22.87N/A
N/A
Cambiar SMID Institutional
USDAUD1.61N/A
N/A
United States Dollar - Australian Dollar
JPYAUD0.01N/A
N/A
Japan Yen - Australian Dollar

IMVT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+0.25%
ROIV - IMVT
50%
Loosely correlated
+2.39%
BRNS - IMVT
48%
Loosely correlated
+2.97%
KYMR - IMVT
43%
Loosely correlated
+0.79%
SNDX - IMVT
38%
Loosely correlated
+0.62%
GRCE - IMVT
38%
Loosely correlated
+8.93%
More